Zura Bio appoints Robert Lisicki as President/COO and Kiran Nistala as CMO; CMO Chris Cabell departs

Zura Bio Ltd

Chris Cabell steps down as Chief Medical Officer and EVP effective Jan 15, 2024; no disagreement with management.
Robert Lisicki appointed President and COO effective Jan 8; base salary $440,000 with 40% target bonus and 1M options grant.
Kiran Nistala joins as EVP Development and CMO; previously VP Immunology at AstraZeneca and roles at GSK.
Lisicki brings experience from Arena Pharmaceuticals (acquired by Pfizer) and Regeneron; Nistala from GSK and AstraZeneca.
Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Lisicki

President and Chief Operating Officer

ZURA · Zura Bio Ltd

Effective: 2024-01-08
Filed: January 8, 2024, 6:59 PM ET

On January 3, 2024, the Company appointed Mr. Robert Lisicki as President and Chief Operating Officer, effective as of January 8, 2024 (the “Commencement Date”).

Departed

Chris Cabell

Chief Medical Officer and Executive Vice President

ZURA · Zura Bio Ltd

Effective: 2024-01-15
Filed: January 8, 2024, 6:59 PM ET

On January 4, 2024, Dr. Chris Cabell and Zura Bio Limited (the “Company”) agreed that he will be stepping down as the Company’s Chief Medical Officer and Executive Vice President, effective on January 15, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Lisicki was appointed as President and Chief Operating Officer at Zura Bio Ltd.

Action: appointed
Role: President and Chief Operating Officer

Exact text from the filing

On January 3, 2024, the Company appointed Mr. Robert Lisicki as President and Chief Operating Officer, effective as of January 8, 2024 (the “Commencement Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Cabell departed as Chief Medical Officer and Executive Vice President at Zura Bio Ltd.

Action: stepping down
Role: Chief Medical Officer and Executive Vice President

Exact text from the filing

On January 4, 2024, Dr. Chris Cabell and Zura Bio Limited (the “Company”) agreed that he will be stepping down as the Company’s Chief Medical Officer and Executive Vice President, effective on January 15, 2024.

View on SEC.gov

Zura Bio Ltd filing history →

Source: SEC EDGAR

accession 0001104659-24-001984

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.